(Press-News.org) ROCKVILLE, Md. – Oct. 23, 2023 – The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, today announced the appointment of Lauren S. Menser, CAE, as its Chief Executive Officer, effective January 3, 2024. Menser will succeed Mary Steele Williams, MNA, MT(ASCP)SM, CAE, after her retirement. AMP’s national search for a new executive leader was administered by an outside consulting firm and overseen by a diverse group of member volunteers.
Menser has served AMP in various capacities for more than 17 years. Since 2016, she has served as Director of Strategic Development, acting as the primary architect of AMP’s alliance, collaboration, and partnership development programs. During her tenure, Menser substantially increased and diversified revenue in her direct areas of responsibility, played a pivotal role in the successful launch of AMP’s international events program, and created the AMP Corporate Advisory Council.
“First, on behalf of the AMP Board Members and more than 2,900 members, I would like to thank Mary Williams for her many years of leadership that helped establish AMP as the highly influential professional society it is today. We wish her and her family all the best in a well-deserved retirement,” said Laura Tafe, MD, AMP President and Search Committee Chair. “The selection of AMP’s next chief executive was among the most important tasks facing us this year. Laurie’s extensive association expertise, combined with her familiarity with challenges impacting molecular diagnostics professionals, made her uniquely qualified for this position. We look forward to her continued contributions to our community and the patients we serve in the years to come.”
Menser is an accomplished senior executive with more than 20 years of experience in scientific association leadership. At AMP, she currently manages the Membership and Marketing & Communications teams, in addition to numerous contractors and consultants. Her certification, Certified Association Executive (CAE), from the American Society of Association Executives, is a marker of her broad knowledge and commitment to continuing education. A longtime champion of Diversity, Equity & Inclusion (DEI) efforts, Menser earned a DEI in the Workplace certificate from the University of South Florida in May 2021, and is a team lead in the design and continuing execution of AMP’s robust DEI Action Plan.
“I am both honored and excited for the opportunity to continue my work at AMP in the role of Chief Executive Officer,” said Menser. “AMP is a remarkable organization with an incredibly bright future. I look forward to partnering with our Board, volunteers, members, and staff as we work towards AMP’s vision of providing global expertise in molecular testing that drives patient care.”
ABOUT AMP
The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP’s 2,900+ members practice various disciplines of molecular diagnostics, including bioinformatics, infectious diseases, inherited conditions, and oncology. Our members are pathologists, clinical laboratory directors, basic and translational scientists, technologists, and trainees that practice in a variety of settings, including academic and community medical centers, government, and industry. Through the efforts of its Board of Directors, Committees, Working Groups, and Members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest-growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high-quality, appropriate testing. For more information, visit www.amp.org and follow AMP on X: @AMPath.
MEDIA CONTACT:
Elisabeth Campbell
ecampbell@amp.org
301-634-7400
###
END
A large study published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.230459 identified 10 predictors of opioid overdose after prescription for chronic pain, which can help clinicians engage in shared decision-making with patients around opioid prescribing.
“The opioid crisis has generated interest in identifying patients at higher risk of addiction or overdose and has led to the development of several screening tools; however, these instruments have either not been validated or shown poor psychometric properties,” writes Dr. Li Wang, a researcher and methodologist at the ...
A team of University of Waterloo researchers has created smart, advanced materials that will be the building blocks for a future generation of soft medical microrobots.
These tiny robots have the potential to conduct medical procedures, such as biopsy, and cell and tissue transport, in a minimally invasive fashion. They can move through confined and flooded environments, like the human body, and deliver delicate and light cargo, such as cells or tissues, to a target position.
The tiny soft robots are a maximum of one centimetre long and are bio-compatible and non-toxic. The robots are made of advanced hydrogel ...
The INTERLACE phase III trial, funded by Cancer Research UK and UCL Cancer Trials Centre, assessed whether a short course of induction chemotherapy (IC) prior to chemoradiation (CRT) could reduce the rate of relapse and death among patients with locally advanced cervical cancer. As part of an analysis of clinical data, the preliminary results will be presented at the European Society for Medical Oncology (ESMO) congress on Sunday 22 October 2023.
The peak incidence of cervical cancer is in women in their early thirties, with around 3,200 new cases each year in the UK. CRT has been the standard treatment for cervical cancer since 1999, but despite improvements ...
New York, NY (October 22, 2023) — A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer. The results were simultaneously reported in The New England Journal of Medicine and at the annual meeting of the European Society for Medical Oncology.
The randomized phase 3 trial, named ”CheckMate 901,” showed significantly improved outcomes in patients who received the immunotherapy nivolumab with a combination of the chemotherapies gemcitabine and cisplatin, ...
Cabozantinib, which targets tumor cell growth and tumor blood vessel growth, sharply improved progression-free survival over placebo in patients with extra-pancreatic and pancreatic neuroendocrine tumors
Boston - A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.
Jennifer Chan, MD, MPH, director of the Program ...
The Alliance for Clinical Trials in Oncology today announced detailed results will be presented at ESMO 2023 from CABINET (A021602), a phase III pivotal trial evaluating cabozantinib compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors (pNET) and a second cohort of patients with advanced extra-pancreatic NET (epNET). The study met the primary objective for each cohort, demonstrating that cabozantinib provided dramatic improvements in median progression-free survival (PFS) for the patients in the pNET and epNET cohorts. ...
MADRID ― Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC). Results from the Phase III CheckMate 77T study were presented today at the 2023 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.
At a median follow-up of 25.4 months, the median EFS with chemotherapy alone was 18.4 months, while the median had not yet been reached for patients receiving perioperative nivolumab, meaning EFS was prolonged ...
Boston – Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial. The trial, led by Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Cancer at Dana-Farber Cancer Institute, showed the risk of progression was reduced by 25-26%.
The results were presented at the annual European Society for Medical Oncology (ESMO) Congress on October ...
The following Lancet papers will be presented at the European Society for Medical Oncology Congress 2023 (#ESMO 2023). The conference will take place between Friday 20th – Tuesday 24th October 2023.
Contact details for corresponding authors are provided should you wish to arrange an interview with the authors. Funding information is listed on the first page of each Article.
**Embargo: 13.00 [BST] / 14.00 [CEST] Friday 20th October 2023**
The Lancet: Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase ...
A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.
The results will be presented at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on Oct. 23, 2023 (poster 1887P) by Primo N. Lara, Jr., MD, lead author on the abstract. ...